TEE
OLMA icon

Tibra Equities Europe’s Olema Pharmaceuticals OLMA Stock Holding History

Tibra Equities Europe’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,300
Closed -$591K – 96
2020
Q4 		$591K Buy
+12,300
New +$577K 0.06% 112

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Tibra Equities Europe's OLMA Position: Q1 2021 in Review

Tibra Equities Europe sold out of Olema Pharmaceuticals (OLMA) in Q1 2021, closing a stake of 12,300 shares — an estimated $591K sold.

Tibra Equities Europe first reported a position in OLMA in Q4 2020 and held it in 1 quarter. The position peaked at $591K in Q4 2020. 74 funds tracked by Wall St. Rank hold OLMA as of Q1 2021.

  • Tibra Equities Europe reported no remaining Olema Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 12,300 Olema Pharmaceuticals shares in Q1 2021, an estimated $591K.
  • Tibra Equities Europe first reported a position in Olema Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Tibra Equities Europe's Olema Pharmaceuticals position peaked at $591K in Q4 2020.
  • 74 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2021.

Based on Tibra Equities Europe's 13F filing for Q1 2021, filed 17 May 2021.